摘要
非酒精性脂肪性肝病(NAFLD)是以肝细胞内脂质蓄积为主要特征的肝脏代谢紊乱疾病,已成为全球范围内慢性肝病的主要病因。20%~30%的NAFLD会进展为非酒精性脂肪性肝炎(NASH),NASH的发展与多种代谢紊乱密切相关。胆汁酸及其受体功能在NASH的发病机制中起着重要作用,胆汁酸受体是治疗NASH重要的靶点。本文对胆汁酸及其受体在NAFLD和NASH发展中的作用,特别是关于法尼醇X受体(FXR)在不同组织(包括肝脏和肠道)中的功能的研究予以综述,介绍基于胆汁酸及其受体的NASH治疗药物的研究进展。
Non-alcoholic fatty liver disease(NAFLD)is a liver metabolic disorder characterized by lipid accumulation in liver cells,and it has become the main cause of chronic liver disease worldwide.20%to 30%of patients with NAFLD were able to progress to non-alcoholic steatohepatitis(NASH),and the development of NASH is closely related to various metabolic disorders.Bile acids and its receptor function play important roles in the pathogenesis of NASH,and bile acid receptors are the important targets for the treatment of NASH.This article reviewed the roles of bile acids and their receptors in the development of NAFLD and NASH,especially the functional research of farnesol X receptors(FXR)in different tissues(including liver and intestine),and introduced the research progress of NASH therapeutic drugs based on bile acids and their receptors.
作者
邵慧娟
郑晓凤
黄俊
马学锋
于晓辉
张久聪
SHAO Huijuan;ZHENG Xiaofeng;HUANG Jun;MA Xuefeng;YU Xiaohui;ZHANG Jiucong(Department of Gastroenterology,the 940th Hospital of Joint Logistic Support Force of the Chinese People′s Liberation Army,Lanzhou,Gansu,730050;the First Clinical Medical College of Gansu University of Traditional Chinese Medicine,Lanzhou,Gansu,730000;Department of Gastroenterology,the Second Hospital of Lanzhou University,Lanzhou,Gansu,730030)
出处
《实用临床医药杂志》
CAS
2023年第9期143-148,共6页
Journal of Clinical Medicine in Practice
基金
甘肃省自然科学基金面上项目(21JR7RA002)
甘肃省自然科学基金青年项目(22JR5RA1012)
中央高校优秀青年团队培育项目(31920220065)
甘肃省非感染性肝病临床医学研究中心(21JR7RA017)。
作者简介
通讯作者:张久聪,E-mail:zhangjiucong@163.com。
